Application of standard and novel prognostic systems in patients with myelodys- plastic syndrome undergoing allogeneic hematopoietic stem cell transplantation

Morozova, Еlena V.; Barabanshikova, Maria V.; Tsvetkov, Nikolai; Melsitova, K. V.; Rudnitskaya, Julia V.; Darskaya, Elena I.; Bondarenko, Sergey N.; Moiseev, Ivan S.; Afanasyev, Boris

doi:10.18620/ctt-1866-8836-2019-8-1-36-45

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6B). The survival rates following HSCT depended on the following items: disease status, graft composition, infectious complications, acute GvHD grade I-II [16]. Interestingly, the evaluation of all existing MDS prognostic scales in our MDS allo-HSCT group did not exert any significant effects on survival after allo-HSCT.…”

Section: Figure 5 Potential Drug Combinations In Personalized Therapy Of High-risk Mdsmentioning

confidence: 68%

“…Long cytopenias after allo-HSCT is associated with higher risk of infectious complications, which are the main cause of posttransplant mortality in MDS patients. All issues described above determine higher post-transplant mortality in MDS compared to the other groups of HSCT recipients [16,17]. Moreover, a significant proportion of patients is lacking HLA-compatible related or unrelated donor, and efficiency of haploidentical HSCT in MDS is still not supported by large studies [18].…”

Section: Hematopoietic Cell Transplantation and Current Therapeutic Optionsmentioning

confidence: 99%

See 1 more Smart Citation

New therapeutic options in myelodysplastic syndrome: literature review and single-center treatment results

Morozova¹,

Tsvetkov²,

Turtanova³

et al. 2021

CTT

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) comprise a group (continuum) of clonal hematopoietic diseases associated with high risk of transformation into acute myeloid leukemia (AML) and unfavorable prognosis. Compared to the other hematologic malignant diseases, there was only a modest improvement in survival of MDS patients over the last years. Allogeneic stem cell transplantation remains the only curative option for these patients, however, most of them are not candidates for transplantation. This review focuses on the long-term outcomes of existing therapies and novel agents that are currently tested at different stages of clinical trials. These include inhibitors of TGFβ, various kinase inhibitors, and immune checkpoint inhibitors. Administration of new therapies in the patients with different pathogenetic MDS variants is discussed.

show abstract

Section: Figure 5 Potential Drug Combinations In Personalized Therapy Of High-risk Mdsmentioning

confidence: 68%

Section: Hematopoietic Cell Transplantation and Current Therapeutic Optionsmentioning

confidence: 99%

New therapeutic options in myelodysplastic syndrome: literature review and single-center treatment results

Morozova¹,

Tsvetkov²,

Turtanova³

et al. 2021

CTT

View full text Add to dashboard Cite

show abstract

Achievements and Challenges of Evidence-Based Medicine in Hematopoietic Stem Cell Transplantation: An Analysis of Single-Center and Multicenter Trials

Afanasyev

Moiseev

Volkov

et al. 2020

Клиническая онкогематология

View full text Add to dashboard Cite

Randomized multicenter trials in the area of hematopoietic stem cell transplantation (HSCT) face considerable challenges, therefore, their amount is relatively small. Most clinical guidelines are based on the data of multicenter registry studies or well-controlled prospective single-center non-randomized studies. To determine the criteria of a well-controlled single-center trial the results of which can be confi rmed by a multicenter analysis, the total of 44 groups of patients from 22 cooperative studies in collaboration with EBMT were analyzed. The results of these studies were compared with single-center data and the results of the planned studies of RM Gorbacheva Scientifi c Research Institute of Pediatric Oncology, Hematology and Transplantation. In 43 % of cases signifi cant diff erences were observed. The probability of diff erences did not decrease with an increasing number of patients in the single-center groups, but became higher (odds ratio 1.037; 95% confi dence interval 1.001-1.074; p = 0.046), which highlights the diff erences in methods of single- and multicenter trials. While analyzing the reasons for signifi cant diff erences the following necessary criteria for high-quali ty single-center trials in the area of HSCT were formulated: 1) conditioning regimens and graft-versus-host disease prophylaxis (if they are not subject of the study) need to be consistent with the most frequently used practices; 2) groups of patients should be status-homogeneous; 3) the trial must not include patients treated more than 5 years before the analysis; 4) patients should receive current antitumor therapy at pre- and post-transplantation stages; 5) each compared group should include more than 30-40 patients

show abstract

Application of standard and novel prognostic systems in patients with myelodys- plastic syndrome undergoing allogeneic hematopoietic stem cell transplantation

Cited by 2 publications

References 31 publications

New therapeutic options in myelodysplastic syndrome: literature review and single-center treatment results

New therapeutic options in myelodysplastic syndrome: literature review and single-center treatment results

Achievements and Challenges of Evidence-Based Medicine in Hematopoietic Stem Cell Transplantation: An Analysis of Single-Center and Multicenter Trials

Contact Info

Product

Resources

About